| Sign In to gain access to subscriptions and/or personal tools. |
A review of the association between antipsychotic use and hyperprolactinaemiaMB BS Eli Lilly and Company Ltd, Basingstoke, UK, beesbeesbees{at}blueyonder.co.uk, bushe_chris{at}lilly.com
Elmfield House MHRC, Halifax, UK
University of Southampton, Royal South Hants Hospital, Southampton, UK Recent evidence linking hyperprolactinaemia to longer-term clinical sequelae, including osteoporosis, hip fractures and possibly breast cancer, is increasing clinical awareness of the relevance of hyperprolactinaemia. A review of the literature finds clinical trials reporting some degree of comparative prolactin data among antipsychotics. Many of the randomised clinical trials (RCTs) do not report categorical rates of hyperprolactinaemia in contrast with the naturalistic studies, making it complex for clinicians to evaluate the extent and severity of hyperprolactinaemia. Hyperprolactinaemia is one of the commonest adverse events reported in clinical trials and can be found in association with all antipsychotics. The highest rates of hyperprolactinaemia are reported in association with risperidone and amisulpride, often as high as 80—90% of all female subjects and consistently greater than with the typical antipsychotics. Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics.
Key Words: prolactin • schizophrenia • hyperprolactinaemia • osteoporosis • antipsychotics • categorical data analysis • breast cancer
Journal of Psychopharmacology, Vol. 22, No. 2 suppl,
46-55 (2008) This article has been cited by other articles:
|
|||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
